載入中
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.
前收盤價
US$6.94
+US$0.14 · +2.06%
盤前
US$6.94
US$0.00 · 0.00%
10月12日 上午8:33 ET
盤中時間採用ET。市場資料可能有所延遲。
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.
日內區間
目前US$6.94
52週區間
目前US$6.94
盤中時間採用ET。市場資料可能有所延遲。
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.
日內區間
目前US$6.94
52週區間
目前US$6.94
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | — | 25.1萬 USD | 3349.2萬 USD | 493.1萬 USD | 200.2萬 USD |
| 銷貨成本 | 259.7萬 USD | — | — | — | — |
| 毛利 | −259.7萬 USD | 25.1萬 USD | 3349.2萬 USD | 493.1萬 USD | 200.2萬 USD |
| 研究與開發 | 6954萬 USD | 5032.8萬 USD | 5025.1萬 USD | 4398.4萬 USD | 4241萬 USD |
| 銷售、一般及管理費用 | 2027萬 USD | 1720.5萬 USD | 1391.2萬 USD | 2077.6萬 USD | 1286.4萬 USD |
| 營業費用 | 8801.3萬 USD | 6753.3萬 USD | 6416.3萬 USD | 6476萬 USD | 5527.4萬 USD |
| 利息收入 | 595.9萬 USD | 534.9萬 USD | 253.5萬 USD | 129.4萬 USD | — |
| 折舊和攤銷 | 259.7萬 USD | 243.1萬 USD | 226.6萬 USD | 115.8萬 USD | 24.8萬 USD |
| 營業利益 | −9061萬 USD | −6728.2萬 USD | −3067.1萬 USD | −5982.9萬 USD | −5327.2萬 USD |
| 淨利 | −8386.5萬 USD | −5849.3萬 USD | −2769.6萬 USD | −5838.8萬 USD | −7182.5萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$37.50
上漲空間 440.35%價格歷史記錄不可用
最高：US$40.00平均的：US$37.50最低：US$35.00評級樣本有限，僅4項
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
